Checkpoint Therapeutics, Inc. (CKPT)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Checkpoint Therapeutics, Inc. (CKPT)
Company Performance

Current Price

as of Oct 16, 2024

$2.82

P/E Ratio

N/A

Market Cap

$124.98M

Description

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Metrics

Overview

  • HQWaltham, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerCKPT
  • Price$2.82+6.82%

Trading Information

  • Market Cap$124.98M
  • Float82.99%
  • Average Daily Volume (1m)480,684
  • Average Daily Volume (3m)413,025
  • EPS-$1.50

Company

  • Revenue$0.08M
  • Rev Growth (1yr)32.26%
  • Net Income-$6.67M
  • Gross MarginN/A
  • EBITDA Margin-16,275.61%
  • EBITDA-$6.67M
  • EV$73.58M
  • EV/Revenue943.34
  • P/EN/A
  • P/S1,320.57
  • P/BN/A
Documents
SEC Filings
8-K (2024-08-12)
8-K (2024-07-25)
8-K (2024-07-03)
8-K (2024-06-24)
8-K (2024-05-14)
8-K (2024-05-10)
8-K (2024-03-22)
8-K (2024-03-18)
8-K (2024-02-02)
8-K (2024-01-30)
8-K (2024-01-05)
8-K (2023-12-18)
8-K (2023-11-13)
8-K (2023-10-03)
8-K (2023-08-14)
8-K (2023-07-31)
8-K (2023-07-27)
8-K (2023-06-13)
8-K (2023-05-24)
8-K (2023-05-15)
8-K (2023-04-04)
8-K (2023-03-31)
8-K (2023-03-10)
8-K (2023-03-02)
8-K (2023-02-22)
8-K (2023-01-04)
10-Q (2024-08-12)
10-Q (2024-05-10)
10-Q (2023-11-13)
10-Q (2023-08-14)
10-Q (2023-05-15)
10-K (2024-03-22)
10-K (2023-03-31)
Factset Street Account
Checkpoint Therapeutics reports Q3 EPS ($0.29) vs FactSet ($0.76) [4 est, ($0.89)-(0.64)] ($1.81, 0.00) (2023-11-13T22:02:21Z)
Checkpoint Therapeutics receives complete response letter from FDA for Cosibelimab solely due to inspection findings at third-party manufacturer ($3.32, 0.00) (2023-12-18T12:09:00Z)
Checkpoint Therapeutics Cosibelimab Pivotal Trial meets primary endpoint ($1.94, 0.00) (2023-10-18T12:41:16Z)